New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Robust Future Ahead for Stem Cell Transplants

Robust Future Ahead for Stem Cell Transplants

December 6, 2018Meir RindeAlthough many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm,
World medicine November 16,2023
Robust Future Ahead for Stem Cell Transplants

Robust Future Ahead for Stem Cell Transplants

December 6, 2018Meir RindeAlthough many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm,
World medicine November 16,2023
Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma

Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma

April 15, 2020Ellie LeickShaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this moda
World medicine November 16,2023
Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma

Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma

April 15, 2020Ellie LeickShaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this moda
World medicine November 16,2023
Daratumumab Maintenance Prolongs Responses Following ASCT and Standard Consolidation/Induction in Myeloma

Daratumumab Maintenance Prolongs Responses Following ASCT and Standard Consolidation/Induction in Myeloma

June 12, 2021Audrey SternbergDaratumumab maintenance therapy yielded an increase in response following autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalido
World medicine November 16,2023
Daratumumab Maintenance Prolongs Responses Following ASCT and Standard Consolidation/Induction in Myeloma

Daratumumab Maintenance Prolongs Responses Following ASCT and Standard Consolidation/Induction in Myeloma

June 12, 2021Audrey SternbergDaratumumab maintenance therapy yielded an increase in response following autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalido
World medicine November 16,2023
Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

November 13, 2023Ryan ScottNicholas C. Rohs, MDCase studies in lung cancer allow for clinicians to gather feedback and discuss the nuances of different situations, according to Nicholas C. Rohs, MD. D
World medicine November 16,2023
Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

November 13, 2023Ryan ScottNicholas C. Rohs, MDCase studies in lung cancer allow for clinicians to gather feedback and discuss the nuances of different situations, according to Nicholas C. Rohs, MD. D
World medicine November 16,2023
Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

June 12, 2022Kristi RosaThe combination of pelabresib and ruxolitinib produced responses that proved to be durable beyond week 24 in patients with myelofibrosis who experienced a suboptimal response t
World medicine November 16,2023
Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

June 12, 2022Kristi RosaThe combination of pelabresib and ruxolitinib produced responses that proved to be durable beyond week 24 in patients with myelofibrosis who experienced a suboptimal response t
World medicine November 16,2023
Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

February 17, 2023Kristi RosaOrca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encou
World medicine November 16,2023
Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

February 17, 2023Kristi RosaOrca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encou
World medicine November 16,2023
Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

May 4, 2021Kristi RosaThe addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow trans
World medicine November 16,2023
Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

May 4, 2021Kristi RosaThe addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow trans
World medicine November 16,2023
KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9, 2021Jamie CesanekThe effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.Carfilzomib-lenalidomide-dexam
World medicine November 16,2023
KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9, 2021Jamie CesanekThe effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.Carfilzomib-lenalidomide-dexam
World medicine November 16,2023
KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25, 2023Caroline SeymourMaintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients wi
World medicine November 16,2023
KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25, 2023Caroline SeymourMaintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients wi
World medicine November 16,2023
FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15, 2023Ryan ScottThe FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an an
World medicine November 16,2023
FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15, 2023Ryan ScottThe FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an an
World medicine November 16,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com